147 related articles for article (PubMed ID: 29465891)
1. Gray matter atrophy in presymptomatic Huntington's patients.
Király A; Kincses ZT; Szabó N; Tóth E; Csete G; Faragó P; Vécsei L
Ideggyogy Sz; 2016 Jul; 69(7-8):261-267. PubMed ID: 29465891
[TBL] [Abstract][Full Text] [Related]
2. White and Gray Matter Abnormalities in Manifest Huntington's Disease: Cross-Sectional and Longitudinal Analysis.
Sweidan W; Bao F; Bozorgzad NS; George E
J Neuroimaging; 2020 May; 30(3):351-358. PubMed ID: 32128927
[TBL] [Abstract][Full Text] [Related]
3. Structural brain correlates of dementia in Huntington's disease.
Martinez-Horta S; Sampedro F; Horta-Barba A; Perez-Perez J; Pagonabarraga J; Gomez-Anson B; Kulisevsky J
Neuroimage Clin; 2020; 28():102415. PubMed ID: 32979842
[TBL] [Abstract][Full Text] [Related]
4. Neurofilament light protein in blood predicts regional atrophy in Huntington disease.
Johnson EB; Byrne LM; Gregory S; Rodrigues FB; Blennow K; Durr A; Leavitt BR; Roos RA; Zetterberg H; Tabrizi SJ; Scahill RI; Wild EJ;
Neurology; 2018 Feb; 90(8):e717-e723. PubMed ID: 29367444
[TBL] [Abstract][Full Text] [Related]
5. Early grey matter changes in structural covariance networks in Huntington's disease.
Coppen EM; van der Grond J; Hafkemeijer A; Rombouts SA; Roos RA
Neuroimage Clin; 2016; 12():806-814. PubMed ID: 27830113
[TBL] [Abstract][Full Text] [Related]
6. Gray matter alterations in Huntington's disease: A meta-analysis of VBM neuroimaging studies.
Wang X; Li Y; Li B; Shang H; Yang J
J Neurosci Res; 2024 Jul; 102(7):e25366. PubMed ID: 38953592
[TBL] [Abstract][Full Text] [Related]
7. The role of iron in gray matter degeneration in Huntington's disease: a magnetic resonance imaging study.
Sánchez-Castañeda C; Squitieri F; Di Paola M; Dayan M; Petrollini M; Sabatini U
Hum Brain Mapp; 2015 Jan; 36(1):50-66. PubMed ID: 25145324
[TBL] [Abstract][Full Text] [Related]
8. Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease.
Minkova L; Gregory S; Scahill RI; Abdulkadir A; Kaller CP; Peter J; Long JD; Stout JC; Reilmann R; Roos RA; Durr A; Leavitt BR; Tabrizi SJ; Klöppel S;
Neuroimage Clin; 2018; 17():312-324. PubMed ID: 29527479
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal atrophy characterization of cortical and subcortical gray matter in Huntington's disease patients.
Ramirez-Garcia G; Galvez V; Diaz R; Bayliss L; Fernandez-Ruiz J; Campos-Romo A
Eur J Neurosci; 2020 Apr; 51(8):1827-1843. PubMed ID: 31705594
[TBL] [Abstract][Full Text] [Related]
10. Grey matter volume loss is associated with specific clinical motor signs in Huntington's disease.
Coppen EM; Jacobs M; van den Berg-Huysmans AA; van der Grond J; Roos RAC
Parkinsonism Relat Disord; 2018 Jan; 46():56-61. PubMed ID: 29128164
[TBL] [Abstract][Full Text] [Related]
11. Multimodal imaging biomarkers in premanifest and early Huntington's disease: 30-month IMAGE-HD data.
D JF; Stout JC; Poudel G; Churchyard A; Chua P; Egan GF; Georgiou-Karistianis N
Br J Psychiatry; 2016 Jun; 208(6):571-8. PubMed ID: 26678864
[TBL] [Abstract][Full Text] [Related]
12. Planning deficits in Huntington's disease: A brain structural correlation by voxel-based morphometry.
Calderon-Villalon J; Ramirez-Garcia G; Fernandez-Ruiz J; Sangri-Gil F; Campos-Romo A; Galvez V
PLoS One; 2021; 16(3):e0249144. PubMed ID: 33760890
[TBL] [Abstract][Full Text] [Related]
13. Variation of selective gray and white matter atrophy in Huntington's disease.
Jech R; Klempír J; Vymazal J; Zidovská J; Klempírová O; Růzicka E; Roth J
Mov Disord; 2007 Sep; 22(12):1783-9. PubMed ID: 17579363
[TBL] [Abstract][Full Text] [Related]
14. Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease.
Squitieri F; Cannella M; Simonelli M; Sassone J; Martino T; Venditti E; Ciammola A; Colonnese C; Frati L; Ciarmiello A
CNS Neurosci Ther; 2009; 15(1):1-11. PubMed ID: 19228174
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat.
Ruocco HH; Bonilha L; Li LM; Lopes-Cendes I; Cendes F
J Neurol Neurosurg Psychiatry; 2008 Feb; 79(2):130-5. PubMed ID: 17615168
[TBL] [Abstract][Full Text] [Related]
16. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.
Byrne LM; Rodrigues FB; Blennow K; Durr A; Leavitt BR; Roos RAC; Scahill RI; Tabrizi SJ; Zetterberg H; Langbehn D; Wild EJ
Lancet Neurol; 2017 Aug; 16(8):601-609. PubMed ID: 28601473
[TBL] [Abstract][Full Text] [Related]
17. Linking white matter and deep gray matter alterations in premanifest Huntington disease.
Faria AV; Ratnanather JT; Tward DJ; Lee DS; van den Noort F; Wu D; Brown T; Johnson H; Paulsen JS; Ross CA; Younes L; Miller MI;
Neuroimage Clin; 2016; 11():450-460. PubMed ID: 27104139
[TBL] [Abstract][Full Text] [Related]
18. Neuroanatomical correlates of prion disease progression - a 3T longitudinal voxel-based morphometry study.
De Vita E; Ridgway GR; White MJ; Porter MC; Caine D; Rudge P; Collinge J; Yousry TA; Jager HR; Mead S; Thornton JS; Hyare H
Neuroimage Clin; 2017; 13():89-96. PubMed ID: 27942451
[TBL] [Abstract][Full Text] [Related]
19. Altered brain iron content and deposition rate in Huntington's disease as indicated by quantitative susceptibility MRI.
Chen L; Hua J; Ross CA; Cai S; van Zijl PCM; Li X
J Neurosci Res; 2019 Apr; 97(4):467-479. PubMed ID: 30489648
[TBL] [Abstract][Full Text] [Related]
20. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study.
Kassubek J; Juengling FD; Kioschies T; Henkel K; Karitzky J; Kramer B; Ecker D; Andrich J; Saft C; Kraus P; Aschoff AJ; Ludolph AC; Landwehrmeyer GB
J Neurol Neurosurg Psychiatry; 2004 Feb; 75(2):213-20. PubMed ID: 14742591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
